Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

Concurrent Babesia gibsoni infection as a negative prognostics indicator of survival in dogs diagnosed with immune-mediated hemolytic anemia: A prospective cohort study.

Topics in companion animal medicine·2026

Same journal

Primary cervical aggressive fibromatosis with spinal cord compression in a cat.

Topics in companion animal medicine·2026

Same journal

Diagnostic Agreement Between Ovarian Ultrasonography and Vaginal Cytology for Estrous Cycle Phase Identification in Bitches.

Topics in companion animal medicine·2026

Same journal

Vestibular syndrome associated with subcutaneous hemangiosarcoma in a cat.

Topics in companion animal medicine·2026

Same journal

Clinical and imaging features with longitudinal follow-up in a guinea pig (Cavia porcellus) with ventricular septal defect.

Topics in companion animal medicine·2026

Same journal

INFLUENCE OF PRIOR ADMINISTRATION OF GABAPENTIN AND INTEGRATIVE PRACTICES ON SEDATION SCORES, PHYSIOLOGICAL PARAMETERS, AND PROPOFOL REQUIREMENT IN CATS SEDATED WITH DEXMEDETOMIDINE.

Topics in companion animal medicine·2026

Search research articles

Related Experiment Video

Updated: May 18, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Antithrombotic therapy.

Stephanie Ann Smith¹

¹Department of Biochemistry, University of Illinois, Urbana, IL 61801, USA. sasmith6@illinois.edu

Topics in Companion Animal Medicine

|October 4, 2012

Summary

Limited options exist for preventing blood clots in pets. While current treatments like heparin and aspirin show some efficacy, new agents are being explored for safer and more effective thromboprophylaxis in companion animals.

Area of Science:

Veterinary Medicine
Pharmacology

Background:

Thrombosis is a serious concern in companion animals, linked to various diseases.
Current thromboprophylaxis options for small animals, such as heparin and aspirin, are limited and have few supporting studies.
Warfarin has a narrow therapeutic window and significant adverse events.

Purpose of the Study:

To review current and emerging thromboprophylactic agents for small animal patients.
To assess the limitations of existing therapies and the potential of new alternatives.

Main Methods:

Review of existing literature on thromboprophylaxis in veterinary and human medicine.
Discussion of novel anticoagulant agents evaluated experimentally in dogs and cats.

Main Results:

Related Experiment Videos

Last Updated: May 18, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Existing options like heparin and aspirin have limited evidence of efficacy and potential risks.
Newer agents used in human medicine show promise but require further veterinary research.
Experimental evaluations in dogs and cats suggest potential for novel thromboprophylactic agents.

Conclusions:

There is a critical need for improved thromboprophylaxis in companion animals.
Emerging anticoagulant therapies may offer safer and more effective solutions for preventing thrombosis in small animals.